Association of British Clinical Diabetologists

Canagliflozin Nationwide Audit

 
Home Live ABCD nationwide audits of new therapies All ABCD nationwide audits Future audits of new therapies ABCD worldwide audits
     

Above: Over 104 weeks canagliflozin led to durable reductions in HbA1c, that were superior to a sulphonylurea. But will this also be the finding in real clinical use? - click to enlarge
 

Above: Over 104 weeks canagliflozin use was associated with a significant reduction in weight compared to weight a increase associated with a sulphonylurea. But will this also be the finding in real clinical use? – click to enlarge
 

Above - canagliflozin significantly reduces systolic blood pressure compared to sitagliptin. Will there be evidence of effects on BP in real clinical use? - click to enlarge
 

Above: the overall population incidence of UTI adverse events was slightly higher with canagliflozin compared with placebo in clinical trials. It will be important to establish what we can about the safety of the agent in real clinical practice - click to enlarge

ABCD nationwide canagliflozin audit on N3
Papers, abstracts, presentations, posters and webcasts emanating from the audit
  

Webcast

Webcast of an ePoster presentation of the results from the ABCD nationwide canagliflozin audit presented by Dr Bob Ryder at the ADA in San Francisco in June 2019. Results from the ABCD nationwide canagliflozin audit

Abstracts

EASD Lisbon, 2017 M Yadagiri, A Robinson, K Darzy, P Winocour, A Strzelecka, IW Gallen, A Bickerton, S Phillips, A Evans, REJ Ryder and ABCD Nationwide Canagliflozin audit contributors. One year metabolic outcomes in the ABCD nationwide canagliflozin audit. Poster presentation 871. Diabetologia 2017, Vol.60 Supplement1: Abstract 871

 

EASD Berlin, 2018 A Puttana, M Yadagiri, P Sen Gupta, I Gallen, A Bickerton, S Phillips, A Evans, D Sennik, R Ryder  2 year metabolic outcomes in the ABCD nationwide canagliflozin audit.Diabetologia 2018, Vol.61 Supplement1: Abstract 637

 

DUK Liverpool, 2019 A Puttanna, M Yadagiri, P Sen Gupta, IW Gallen, A Bickerton, S Phillips, A Evans, Sennik, REJ Ryder and ABCD nationwide canagliflozin audit contributors. Two year metabolic outcomes in the Association of British Clinical Diabetologist (ABCD) Nationwide Canagliflozin Audit: a comparison of glycaemic improvements. Poster Presentation A comparison of glycaemic improvements, Diabetic Medicine 2019. 36 (Suppl 1): Abstract A3.

 

ADA, San Fransisco 2019 R E.J. Ryder, S M. Phillips, A Evans, D K. Sennik, A Rohilla, A Bickerton, K Thong, M Yadagiri, M L. Cull, M C. Wyres, P Winocour, K H. Darzy, A Strzleka, S G. Gohil, A Gallagher, I W. Gallen, Relationship Between Canagliflozin Treatment Response and Duration of Diabetes: The Association of British Clinical Diabetologists (ABCD) Nationwide Canagliflozin Audit. Diabetes 2019 Jun; 68 (Supplement 1): 1209-P.

 


Posters

EASD Lisbon, 2017

EASD Berlin, 2018

DUK Liverpool, 2019

ADA, San Fransisco, 2019

    Register for the canagliflozin audit: UK

Register for the canagliflozin audit: Northern Ireland and non-UK

Register simultaneously for ALL 3 SGLT2 audits: canagliflozin, dapagliflozin and empagliflozin

Access the on-line tool
(UK: you need to be on N3)

Access the worldwide on-line tool
(Northern Ireland and non-UK)

Canagliflozin audit objectives

Order preprinted data entry forms

Download first visit data entry form

Download follow up visit data entry form

Further information- contact us

Main ABCD homepage

     

The ABCD nationwide canagliflozin audit is an independent audit supported by an unrestricted grant from Janssen

Working to support high quality diabetes care in the UK